Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma

GC33 is a humanized mAb against human glypican-3 (GPC3). In the first-in-human study carried out in the USA, GC33 was well tolerated and showed preliminary antitumor activity in patients with advanced hepatocellular carcinoma. This study aimed to assess the safety, tolerability, and pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Masafumi, Ohkawa, Shinichi, Okusaka, Takuji, Mitsunaga, Shuichi, Kobayashi, Satoshi, Morizane, Chigusa, Suzuki, Ikue, Yamamoto, Shunsuke, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317809/
https://www.ncbi.nlm.nih.gov/pubmed/24521523
http://dx.doi.org/10.1111/cas.12368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317809/
https://www.ncbi.nlm.nih.gov/pubmed/24521523
http://dx.doi.org/10.1111/cas.12368

Ejemplares similares